​

TScan Therapeutics (TCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TCRX Stock Forecast

TScan Therapeutics (TCRX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $1.00, with a high of $1.00 and a low of $1.00. This represents a 203.03% increase from the last price of $0.33.

- $1 $2 $3 $4 $5 $6 $7 $8 $9 High: $1 Avg: $1 Low: $1 Last Closed Price: $0.33

TCRX Stock Rating

TScan Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 4 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 4 4 Strong Sell Sell Hold Buy Strong Buy

TCRX Price Target Upside V Benchmarks

TypeNameUpside
StockTScan Therapeutics203.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts222
Avg Price Target$1.00$1.00$1.00
Last Closing Price$0.33$0.33$0.33
Upside/Downside203.03%203.03%203.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26141--6
Aug, 26141--6
Jul, 26141--6
Jun, 26141--6
May, 26141--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2026Andres MaldonadoH.C. Wainwright$1.00$0.36177.78%203.03%
Sep 02, 2026Wedbush$1.00$0.40150.00%203.03%
Mar 07, 2025Barclays$3.00$1.9851.52%809.09%
May 16, 2024Justin ZelinBTIG$12.00$8.9334.38%3536.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 08, 2026H.C. WainwrightBuyNeutraldowngrade
Sep 08, 2026H.C. WainwrightBuyReducedowngrade
Sep 02, 2026NeedhamUnderperformHolddowngrade
Sep 02, 2026WedbushBuyNeutraldowngrade
Aug 13, 2026BenchmarkBuyBuyhold
Nov 04, 2025BTIGBuyNeutraldowngrade
May 07, 2025H.C. WainwrightBuyBuyhold
Aug 13, 2024WedbushBuyBuyhold
Jun 04, 2024NeedhamUnderperformUnderperformhold
May 16, 2024BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.74$-1.36$-1.14$-1.00---
Avg Forecast$-6.39$-2.76$-1.54$-1.27$-1.28$-1.33$-1.12$-0.92
High Forecast$-0.26$-0.55$-1.32$-1.23$-1.09$-1.04$-0.81$-0.04
Low Forecast$-14.88$-5.33$-1.65$-1.31$-1.45$-1.57$-1.60$-1.90
Surprise %-68.23%-0.72%-11.69%-10.24%-21.88%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.14M$13.54M$21.05M$2.82M----
Avg Forecast$11.32M$13.89M$16.86M$3.61M$6.98M$11.95M$26.31M$69.32M
High Forecast$22.88M$23.84M$18.54M$4.69M$12.73M$21.79M$47.97M$126.38M
Low Forecast$2.96M$5.34M$15.65M$2.92M$1.85M$3.16M$6.96M$18.33M
Surprise %-10.40%-2.58%24.84%-21.96%----

Net Income Forecast

$-1B $-800M $-600M $-400M $-200M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.63M$-66.22M$-89.22M$-127.50M$-129.77M---
Avg Forecast$-419.31M$-181.06M$-89.22M$-83.10M$-83.23M$-85.45M$-79.05M$-60.35M
High Forecast$-16.97M$-36.15M$-86.28M$-80.49M$-71.45M$-67.90M$-53.14M$-2.64M
Low Forecast$-976.21M$-349.53M$-108.21M$-85.71M$-95.02M$-103.00M$-104.96M$-124.93M
Surprise %-88.40%-63.43%-53.42%55.91%---

TCRX Forecast FAQ

Is TScan Therapeutics stock a buy?

TScan Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that TScan Therapeutics is a favorable investment for most analysts.

What is TScan Therapeutics's price target?

TScan Therapeutics's price target, set by 8 Wall Street analysts, averages $1 over the next 12 months. The price target range spans from $1 at the low end to $1 at the high end, suggesting a potential 203.03% change from the previous closing price of $0.33.

How does TScan Therapeutics stock forecast compare to its benchmarks?

TScan Therapeutics's stock forecast shows a 203.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for TScan Therapeutics over the past three months?

  • September 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is TScan Therapeutics’s EPS forecast?

TScan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.33, marking a 33.00% increase from the reported $-1 in 2025. Estimates for the following years are $-1.12 in 2027, and $-0.92 in 2028.

What is TScan Therapeutics’s revenue forecast?

TScan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $11.95M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $26.31M, and $69.32M for 2028.

What is TScan Therapeutics’s net income forecast?

TScan Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-85.45M, representing a -34.15% decrease from the reported $-130M in 2025. Projections indicate $-79.048M in 2027, and $-60.352M in 2028.